Global Standalone Fluorescence Imaging Systems Market Size (2023 – 2030)

In 2022, the Global Standalone Fluorescence Imaging Systems Market was valued at USD 541.47 million and is projected to reach a market size of USD 800 million by 2030. Over the forecast period of 2023-2030, the market is projected to grow at a CAGR of 5%.

Industry Overview

Whether the technique in question is epifluorescence microscopy (excitation and observation of fluorescence from above the specimen), more sophisticated confocal microscopy, which provides a clean, 3-D image, or fluorescence-lifetime imaging microscopy (FLIM), which measures the lifetime of the fluorophore signal, fluorescence imaging is one of our most effective tools for the study of molecular biology and biochemistry. A light source, such as a xenon or mercury lamp, excitation and emission filters, and a dichroic mirror or beam splitter are essential components of all fluorescence imaging systems. A key advantage of the method is sensitive detection of biological molecules, as well as multicolour detection, which removes sample-to-sample fluctuation and is cost- and time-efficient.

Optical imaging has a very high sensitivity for tracking disease development and assessing medication candidate effects. For phenotyping, medication development, and giving a fundamental understanding of disease mechanisms, preclinical imaging is crucial. The main goal is to accelerate the time and cost of medication research and development while increasing the likelihood of clinical success. The practice of medicine today and how health issues are addressed and resolved are being transformed by translational research. As a bridge between molecular discoveries and clinical implementation in diagnostics and therapies, the use of small-animal models in fundamental and preclinical sciences is an essential part of these kinds of research and development endeavours.

The ability to noninvasively scan and monitor molecular processes within tumours is demonstrated by high-resolution modalities, and molecular imaging is an essential tool for cancer researchers. In important fields like infection, oncology, cardiology, and neurology, research continues to expand its horizons by combining high-resolution modalities like micro-CT or micro-MRI with highly sensitive techniques that provide functional information, such as micro-PET or micro-SPECT. This combination not only contributes to a better understanding of disease mechanisms but also to the provision of effective and distinctive tools to evaluate new chemical entities and candidate drugs. For instance, an ultrahigh-resolution E-Class U-SPECT6/CT equipment for preclinical imaging was installed at Kawasaki Medical University in 2019, the city of Yokohama's research centre for cutting-edge medical science and services.

Impact of Covid-19 on the industry

In addition, the COVID-19 pandemic forced a massive restructuring of clinics and hospitals around the world to increase the hospital capacity for COVID-19 patients. Due to the exponentially increasing COVID-19 instances, non-essential treatments could potentially be delayed. In contrast, several preclinical research projects and initiatives by different researchers, businesses, and the government—including clinical trials for the efficacy and safety—of the treatment of COVID-19—boosted the development of the optical preclinical imaging industry.

In addition, untapped emerging markets are anticipated to present prospective growth prospects as a result of advancements in healthcare infrastructure, an increase in unmet medical demands, and a boost in R&D activities. Additionally, there is a growing opportunity for key players to participate in the optical preclinical imaging market due to the availability of numerous institutions offering such minimally invasive treatments.

Market Drivers

Increasing technological advancement in the industry will drive the market growth

Technology developments in molecular imaging are mostly to blame for the rise in the use of optical preclinical imaging. The impact of nuclear medicine and molecular imaging on diagnosis and treatment has significantly improved and is still growing. One of the main factors influencing the evolution of the nuclear medicine and molecular imaging industry is the rise in the prevalence of chronic diseases, a significant increase in the aging population, and more constrained global resources. Computed tomography (CT), magnetic resonance imaging (MRI), positron emission tomography (PET)/CT, and single-photon emission computed tomography (SPECT)/CT are examples of advanced imaging and hybrid modalities that are becoming increasingly popular. Additionally, molecular imaging has made it possible to tailor therapy to each patient's needs. The demand for non-invasive small animal imaging methods has also significantly increased.

Rising cases of chronic disease will propel the market growth

Increases in chronic diseases and the advent of new diseases have been correlated with population growth. New drug compounds have also been developed as a result of this research. Before these new drug candidates are tested on people, preclinical research and clinical trials are carried out on animals to determine their safety and efficacy. Additionally, market growth is boosted by an increase in preclinical research funding from both public and private institutions. The expensive price of optical preclinical imaging, however, is a major barrier to the global industry. Additionally, optical preclinical imaging equipment needs routine maintenance, which adds to the cost and slows the expansion of the global market.

Growing Adoption of NIR fluorescence Imaging System for Plastic/Reconstructive Surgeries to Drive Market

Due to its capability for perioperative, real-time anatomical identification and guidance, the NIR fluorescence imaging technology holds considerable potential for the future of plastic surgery. A data-driven, on-the-table technique for surgeons to find poorly perfused flaps is NIR fluorescence imaging. Flap colour and capillary refilling are two conventional measures of flap evaluation that are highly subjective and may result in incorrect clinical judgment. NIR fluorescence imaging devices are becoming more dependable and safer during difficult reconstructive treatments. Breast reconstruction procedures can be performed using a variety of commercial near-infrared fluorescence imaging systems, including SPY Elite, FLARE, IC-View, PDE-Neo, and Fluobeam 800.

Market Restraints

The high initial cost will challenge the market growth

The Standalone Fluorescence Imaging System is expensive to set up. These systems require complex machinery and trained professionals to produce these systems which increases the cost of production.

STANDALONE FLUORESCENCE IMAGING SYSTEMS MARKET REPORT COVERAGE:

This research report on the global standalone fluorescence imaging systems market has been segmented and sub-segmented based on, type, application and Geography & region.

Global Fluorescence Imaging Systems Market- By Type

• Laser Diodes
• Light Emitting Diodes
• Filtered Lamp Sources

The laser diode, light-emitting diode, and filtered lamp source segments make up the global market for near-infrared fluorescence imaging systems. With a market share of more than 45% in 2021, the laser diode category dominated the global market for near-infrared fluorescence imaging systems. The use of laser diode improves the surgeon's capacity to judge perfusion, which benefits patient outcomes. Additionally, open procedures like cardiothoracic surgery and breast and other types of reconstruction are made possible by laser diode-based fluorescence imaging, such as "SPY Elite," which allows surgeons to see intraoperatively the microvascular blood flow in the tissue.

Global Fluorescence Imaging Systems Market- By Application

• Cancer Surgeries
• Cardiovascular Surgeries
• Preclinical Imaging
• Plastic/Reconstructive Surgeries
• Thyroid Surgeries
• Others

The global standalone fluorescent imaging system market has been segmented based on application into thyroid surgeries, plastic/reconstructive surgeries, preclinical imaging, cancer surgeries, and cardiovascular surgeries. The market for near-infrared fluorescence imaging systems was dominated by cancer procedures in 2021, accounting for more than 51% of the market. One of the key factors that are anticipated to increase the cancer surgeries market over the forecast period is the global rise in cancer incidence. The World Health Organization (WHO) estimates that cancer will be responsible for around 10 million deaths worldwide in 2020. In addition, 2.26 million new instances of breast cancer were discovered in 2020, with close to 685,000 deaths.

The use of novel, cutting-edge surgical tools like near-infrared fluorescence lymphatic imaging (NIRFLI) is essential. With the use of this technology, patients with chronic venous insufficiency (CVI) can see lymphatic dysfunction (also known as lymphedema) in its early stages.

Global Fluorescence Imaging Systems Market- By Geography & Region

• North America
• Europe
• Asia-Pacific
• Latin America
• The Middle East and Africa

In terms of volume, the standalone fluorescent imaging system market was dominated by North America in 2021, accounting for almost 40% of the total market. The market for near-infrared fluorescence imaging systems in North America is anticipated to grow significantly throughout the forecast period due to several factors, including technological advancements, rising costs for cancer and heart disease treatment, and strong support from government authorities.

Due to the rise in the prevalence of chronic diseases like cancer and CVDs, the Asia Pacific region is predicted to be a very appealing market during the analysed period. The market for near-infrared fluorescence imaging systems in the Asia Pacific is also boosted by the substantial presence of key players like Olympus Corporation, Hamamatsu Photonics K.K., Shimadzu Corporation, and Mizuho Medical Co., Ltd. and their cutting-edge innovations in medical imaging modalities.

In comparison to the Middle East and Africa, Latin America is a prominent consumer of near-infrared fluorescence imaging equipment. In addition, the market in Latin America is anticipated to grow more quickly than the markets in the Middle East and Africa.

Global Fluorescence Imaging Systems Market- By Companies

1. Carl Zeiss Meditec AG
2. Fluoptics
3. Hamamatsu Photonics K.K
4. KARL STORZ SE & Co. KG
5. Mizuho Medical Innovation
6. Olympus
7. PULSION MEDICAL SYSTEMS SE
8. Shimadzu Corporation
9. Stryker
10. Other prominent players

NOTABLE HAPPENINGS IN THE GLOBAL STANDALONE FLUORESCENCE IMAGING SYSTEM MARKET IN THE RECENT PAST:

• Merger & Acquisition: - In 2022, To further bolster its position as a solution provider, Carl Zeiss Meditec announced the acquisition of two surgical equipment makers (Kogent Surgical, LLC and Katalyst Surgical, LLC).
• Merger & Acquisition: - In 2021, Hamamatsu Photonics K.K. announces the creation of a subsidiary and the acquisition of shares of Danish company NKT Photonics A/S by a consolidated subsidiary. With its photonic crystal fibre production method for ultrashort pulse laser amplification and fibre transmission, NKT Photonics is a manufacturer of fibre lasers.
• Merger & Acquisition: - In 2019, To further develop its Healthcare Business in North America, Shimadzu Medical Systems USA, a division of Shimadzu Corporation (hereafter "Shimadzu"), purchased CORE Medical Imaging, Inc. (hereinafter "CMI").